• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非黑色素瘤皮肤癌管理的综合护理路径与中心辐射模式:意大利医院皮肤科医生协会(ADOI)的提议

Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: A proposal of the Italian Association of Hospital Dermatologists (ADOI).

作者信息

Fania Luca, Massone Cesare, Cusano Francesco, Fantini Fabrizio, Dellambra Elena, Samela Tonia, Passarelli Francesca, Morese Roberto, Tartaglione Tommaso, Maggiore Marino, Gentile Piercarlo, Falchetto Osti Mattia, Sampogna Francesca, Pallotta Sabatino, Abeni Damiano, Marchetti Paolo, Naldi Luigi

机构信息

IDI-IRCCS, Dermatological Research Hospital, Rome.

Galliera Hospital, Genova.

出版信息

Dermatol Reports. 2021 Aug 5;13(2):9278. doi: 10.4081/dr.2021.9278. eCollection 2021 Aug 1.

DOI:10.4081/dr.2021.9278
PMID:34497705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8404423/
Abstract

The term (NMSC) refers to skin cancer different from melanoma, and it is usually restricted to basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and their pre-cancerous lesions, , actinic keratosis. These conditions represent the most frequent tumors in Caucasians and are characterized by an increasing incidence worldwide and a high socio-economic impact. The term (ICP) refers to "a complex intervention for the mutual decision making and organization of care processes for a well-defined group of patients during a well-defined period". The purpose of this paper is to present a proposal from the Italian Association of Hospital Dermatologists (ADOI) for an ICP organization of care of NMSC, considering the hub-and-spoke model in the different geographical areas. This proposal is based on the most recent literature and on documents from the Italian Association of Medical Oncology (AIOM), the European consensus-based interdisciplinary guidelines from the European Association of Dermato- Oncology (EADO), and the National Comprehensive Cancer Network (NCCN). We initially discuss the NMSC outpatient clinic, the role of the multidisciplinary working groups, and the hub-and-spoke model regarding this topic. Then, we define the ICP processes specific for BCC and SCC. The ICP for NMSC is an innovative strategy to guarantee the highest possible quality of health care while the hub-andspoke model is crucial for the organization of different health care structures. Considering the importance on this topic, it is essential to create a valid ICP together with an efficient organization within the different geographical areas.

摘要

非黑色素瘤皮肤癌(NMSC)这一术语指的是不同于黑色素瘤的皮肤癌,通常局限于基底细胞癌(BCC)、鳞状细胞癌(SCC)及其癌前病变,即光化性角化病。这些病症是白种人中最常见的肿瘤,其特点是在全球范围内发病率不断上升,且具有较高的社会经济影响。综合照护方案(ICP)这一术语指的是“在明确的时间段内,针对明确的一组患者进行共同决策和护理流程组织的复杂干预措施”。本文旨在提出意大利医院皮肤科医生协会(ADOI)关于非黑色素瘤皮肤癌综合照护方案组织的建议,同时考虑不同地理区域的枢纽-辐条模式。该建议基于最新文献以及意大利医学肿瘤学协会(AIOM)的文件、欧洲皮肤肿瘤学协会(EADO)基于共识的跨学科指南和美国国立综合癌症网络(NCCN)。我们首先讨论非黑色素瘤皮肤癌门诊、多学科工作组的作用以及关于该主题的枢纽-辐条模式。然后,我们定义基底细胞癌和鳞状细胞癌特有的综合照护方案流程。非黑色素瘤皮肤癌的综合照护方案是一种创新策略,可确保尽可能高的医疗质量,而枢纽-辐条模式对于不同医疗结构的组织至关重要。鉴于该主题的重要性,在不同地理区域内创建一个有效的综合照护方案并建立高效的组织至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/144a74b047a7/dr-13-2-9278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/ddbd0d0395b9/dr-13-2-9278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/aa931206608f/dr-13-2-9278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/2734030f265e/dr-13-2-9278-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/144a74b047a7/dr-13-2-9278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/ddbd0d0395b9/dr-13-2-9278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/aa931206608f/dr-13-2-9278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/2734030f265e/dr-13-2-9278-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8621/8404423/144a74b047a7/dr-13-2-9278-g004.jpg

相似文献

1
Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: A proposal of the Italian Association of Hospital Dermatologists (ADOI).非黑色素瘤皮肤癌管理的综合护理路径与中心辐射模式:意大利医院皮肤科医生协会(ADOI)的提议
Dermatol Reports. 2021 Aug 5;13(2):9278. doi: 10.4081/dr.2021.9278. eCollection 2021 Aug 1.
2
[The integrated care pathway for non melanoma skin cancer: the Istituto Dermopatico dell'Immacolata - IRCCS experience in Rome.].[非黑色素瘤皮肤癌的综合护理路径:罗马圣心皮肤病研究所-IRCCS的经验。]
Recenti Prog Med. 2020 Dec;111(12):749-760. doi: 10.1701/3509.34966.
3
Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians.医生对非黑色素瘤皮肤癌(NMSC)和光化性角化病(AK)的知晓情况、了解程度及态度。
Int J Dermatol. 2004 Sep;43(9):638-42. doi: 10.1111/j.1365-4632.2004.02124.x.
4
Health economic evaluation of non-melanoma skin cancer and actinic keratosis.非黑色素瘤皮肤癌和光化性角化病的卫生经济学评估。
Pharmacoeconomics. 2004;22(2):83-94. doi: 10.2165/00019053-200422020-00002.
5
Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers.光化性角化病和非黑素瘤皮肤癌中的病毒 DNA 检测和 RAS 突变。
Br J Dermatol. 2010 Feb 1;162(2):325-31. doi: 10.1111/j.1365-2133.2009.09480.x. Epub 2009 Aug 29.
6
Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression.患者报告的非黑素瘤皮肤癌和光化性角化病患者的健康结局:一项大规模观察性研究分析诊断和疾病进展影响的结果。
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1138-1146. doi: 10.1111/jdv.14703. Epub 2018 Jan 12.
7
CONSENSUS REPORT: Recognizing non-melanoma skin cancer, including actinic keratosis, as an occupational disease - A Call to Action.共识报告:将包括光化性角化病在内的非黑素瘤皮肤癌认定为职业病——行动呼吁
J Eur Acad Dermatol Venereol. 2016 Apr;30 Suppl 3:38-45. doi: 10.1111/jdv.13608.
8
[Management of non melanoma skin cancer by the general practitioner].全科医生对非黑色素瘤皮肤癌的管理
Rev Med Brux. 2016;37(4):212-220.
9
The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force.皮肤肿瘤学的发展领域及皮肤科医生的作用:欧洲皮肤肿瘤学会(EADO)、欧洲皮肤病学和性病学会(EADV)以及各特别工作组、欧洲皮肤科和性病学联合会(EDF)、国际皮肤科学会(IDS)、欧洲皮肤病学和性病学联合会 - 欧洲医学专业委员会(EBDV - UEMS)和欧洲癌症研究与治疗组织皮肤淋巴瘤特别工作组的立场文件。
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2183-2197. doi: 10.1111/jdv.16849. Epub 2020 Aug 24.
10
Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group.电离辐射治疗后基底细胞癌和鳞状细胞癌的风险。皮肤癌预防研究小组。
J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53. doi: 10.1093/jnci/88.24.1848.

引用本文的文献

1
Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020).电化学疗法治疗皮肤鳞状细胞癌:INSPECT经验(2008 - 2020年)
Front Oncol. 2022 Sep 20;12:951662. doi: 10.3389/fonc.2022.951662. eCollection 2022.

本文引用的文献

1
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.西妥昔单抗治疗后局部晚期基底细胞癌:一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14.
2
Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.皮肤鳞状细胞癌:从病理生理学到新型治疗方法
Biomedicines. 2021 Feb 9;9(2):171. doi: 10.3390/biomedicines9020171.
3
[The integrated care pathway for non melanoma skin cancer: the Istituto Dermopatico dell'Immacolata - IRCCS experience in Rome.].
[非黑色素瘤皮肤癌的综合护理路径:罗马圣心皮肤病研究所-IRCCS的经验。]
Recenti Prog Med. 2020 Dec;111(12):749-760. doi: 10.1701/3509.34966.
4
Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.基底细胞癌:从病理生理学到新型治疗方法
Biomedicines. 2020 Oct 23;8(11):449. doi: 10.3390/biomedicines8110449.
5
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).帕博利珠单抗单药治疗复发性或转移性皮肤鳞状细胞癌:一项单臂 II 期试验(KEYNOTE-629)。
J Clin Oncol. 2020 Sep 1;38(25):2916-2925. doi: 10.1200/JCO.19.03054. Epub 2020 Jul 16.
6
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.西妥昔单抗治疗转移性皮肤鳞状细胞癌的 2 期研究:固定剂量、体重为基础剂量的长期结局的初步分析。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000775.
7
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.欧洲多学科指南:侵袭性鳞状细胞皮肤癌——第 1 部分:流行病学、诊断和预防。
Eur J Cancer. 2020 Mar;128:60-82. doi: 10.1016/j.ejca.2020.01.007. Epub 2020 Feb 26.
8
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.索纳替尼和维莫德吉治疗局部晚期基底细胞癌患者:联合专家意见
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1944-1956. doi: 10.1111/jdv.16230. Epub 2020 Mar 4.
9
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.西妥昔单抗治疗局部晚期皮肤鳞状细胞癌:一项开放标签、2 期、单臂试验的结果。
Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. Epub 2020 Jan 14.
10
Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline.皮肤基底细胞癌和鳞状细胞癌的确定性和术后放射治疗:美国放射肿瘤学会临床实践指南的执行摘要。
Pract Radiat Oncol. 2020 Jan-Feb;10(1):8-20. doi: 10.1016/j.prro.2019.10.014. Epub 2019 Dec 9.